Common Treatment-Emergent Adverse Events (≥5% in any treatment group)
Study CDISCPILOT01 — Safety Analysis Set
	Placebo	Xanomeline Low Dose	Xanomeline High Dose	Total	
	(N=86)	(N=96)	(N=72)	(N=254)	
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	21 (24.4%)	51 (53.1%)	36 (50.0%)	108 (42.5%)	
APPLICATION SITE PRURITUS	6 (7.0%)	23 (24.0%)	21 (29.2%)	50 (19.7%)	
APPLICATION SITE ERYTHEMA	3 (3.5%)	13 (13.5%)	14 (19.4%)	30 (11.8%)	
APPLICATION SITE DERMATITIS	5 (5.8%)	9 (9.4%)	7 (9.7%)	21 (8.3%)	
APPLICATION SITE IRRITATION	3 (3.5%)	9 (9.4%)	9 (12.5%)	21 (8.3%)	
APPLICATION SITE VESICLES	1 (1.2%)	5 (5.2%)	5 (6.9%)	11 (4.3%)	
FATIGUE	1 (1.2%)	5 (5.2%)	5 (6.9%)	11 (4.3%)	
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	20 (23.3%)	39 (40.6%)	39 (54.2%)	98 (38.6%)	
PRURITUS	8 (9.3%)	21 (21.9%)	25 (34.7%)	54 (21.3%)	
ERYTHEMA	8 (9.3%)	14 (14.6%)	14 (19.4%)	36 (14.2%)	
RASH	5 (5.8%)	13 (13.5%)	8 (11.1%)	26 (10.2%)	
HYPERHIDROSIS	2 (2.3%)	4 (4.2%)	8 (11.1%)	14 (5.5%)	
SKIN IRRITATION	3 (3.5%)	6 (6.3%)	5 (6.9%)	14 (5.5%)	
BLISTER	0 (0.0%)	5 (5.2%)	1 (1.4%)	6 (2.4%)	
NERVOUS SYSTEM DISORDERS	8 (9.3%)	22 (22.9%)	23 (31.9%)	53 (20.9%)	
DIZZINESS	2 (2.3%)	9 (9.4%)	10 (13.9%)	21 (8.3%)	
HEADACHE	3 (3.5%)	3 (3.1%)	5 (6.9%)	11 (4.3%)	
SYNCOPE	0 (0.0%)	5 (5.2%)	2 (2.8%)	7 (2.8%)	

Common Treatment-Emergent Adverse Events (≥5% in any treatment group)
Study CDISCPILOT01 — Safety Analysis Set
	Placebo	Xanomeline Low Dose	Xanomeline High Dose	Total	
	(N=86)	(N=96)	(N=72)	(N=254)	
GASTROINTESTINAL DISORDERS	17 (19.8%)	15 (15.6%)	19 (26.4%)	51 (20.1%)	
DIARRHOEA	9 (10.5%)	5 (5.2%)	3 (4.2%)	17 (6.7%)	
VOMITING	3 (3.5%)	4 (4.2%)	6 (8.3%)	13 (5.1%)	
NAUSEA	3 (3.5%)	3 (3.1%)	6 (8.3%)	12 (4.7%)	
SALIVARY HYPERSECRETION	0 (0.0%)	0 (0.0%)	4 (5.6%)	4 (1.6%)	
CARDIAC DISORDERS	12 (14.0%)	14 (14.6%)	14 (19.4%)	40 (15.7%)	
SINUS BRADYCARDIA	2 (2.3%)	7 (7.3%)	8 (11.1%)	17 (6.7%)	
MYOCARDIAL INFARCTION	4 (4.7%)	2 (2.1%)	4 (5.6%)	10 (3.9%)	
INFECTIONS AND INFESTATIONS	16 (18.6%)	9 (9.4%)	13 (18.1%)	38 (15.0%)	
NASOPHARYNGITIS	2 (2.3%)	4 (4.2%)	6 (8.3%)	12 (4.7%)	
UPPER RESPIRATORY TRACT INFECTION	6 (7.0%)	1 (1.0%)	3 (4.2%)	10 (3.9%)	
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	8 (9.3%)	9 (9.4%)	10 (13.9%)	27 (10.6%)	
COUGH	1 (1.2%)	5 (5.2%)	5 (6.9%)	11 (4.3%)	
Reduced variant: only preferred terms reported by at least 5% of subjects in at least one treatment group are shown. The full display is Section 14.
Subjects are counted once per system organ class and once per preferred term, regardless of how many events they reported.
Percentages are based on the number of subjects in the safety analysis set for each treatment group.
System organ classes and preferred terms are sorted by descending subject count.
The Total column pools all treatment groups; the 5% threshold applied to the in-text variant is evaluated on the treatment columns only, never on Total.	
Source: adae, adsl (pharmaverseadam). Data cut-off: 2014-07-01. open.csr display t-ae-common (in-text variant); generated from the committed ARD.